According to Bellerophon Therapeutics 's latest financial reports the company's current revenue (TTM) is $5.64 M. In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $5.64 M | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Abbott Laboratories ABT | $40.10 B | 711,052.48% | ๐บ๐ธ USA |
Baxter BAX | $14.94 B | 264,953.19% | ๐บ๐ธ USA |
Lantheus Holdings LNTH | $1.29 B | 22,886.33% | ๐บ๐ธ USA |
Abeona Therapeutics
ABEO | $3.5 M | -37.94% | ๐บ๐ธ USA |